Common Contracts
6 similar Control and Severance Agreement contracts by Athira Pharma, Inc.
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • August 16th, 2021 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Rachel Lenington (“Executive”), effective as of June 14, 2021 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • August 16th, 2021 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Mark Worthington (“Executive”), effective as of June 1, 2021 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • September 14th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Hans Moebius (“Executive”), effective as of the effective date of the Company’s registration statement relating to the Company’s initial public offering (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • September 9th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Glenna Mileson (“Executive”), effective as of September 8, 2020 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • September 9th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Mark Litton (“Executive”), effective as of September 8, 2020 (the “Effective Date”).
CHANGE IN CONTROL AND SEVERANCE AGREEMENTControl and Severance Agreement • September 9th, 2020 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Leen Kawas (“Executive”), effective as of September 8, 2020 (the “Effective Date”).
